Pharmacogenetic analyses of variations of measures of cardiovascular risk in Alzheimer's dementia.

Background & objectives: Neurodegeneration affects blood pressure variations, while renal function and cerebral perfusion are impaired by vascular risk factors. This study was aimed to estimate variations of measures of cardiovascular risk in Alzheimer's dementia by pharmacogenetic analyses of the effects of angiotensin-converting enzyme (ACE) inhibitors and statins. Methods: Consecutive patients were prospectively followed to study variations of creatinine clearance and blood pressure for one year, estimated by correlating the effects of ACE inhibitors with the ACE Alu I/D polymorphism and genotypes or haplotypes of rs1800764 or rs4291, and the effects of statins with LDLR (low-density lipoprotein receptor) genotypes or haplotypes of rs11669576 (exon 8) or rs5930 (exon 10), or genotypes of rs2695121 (liver X receptor ß gene). Variations of the coronary heart disease (CHD) risk according to these cardiovascular measures were also explored. Results: All polymorphisms of the 193 patients were in Hardy-Weinberg equilibrium. Genetic determinants of cardiovascular effects affected the individual variability of the response to ACE inhibitors and statins. ACE inhibitors, but not statins, reduced blood pressure for all patients. ACE inhibitors protected carriers of alleles that supposedly decrease serum ACE levels (rs1800764-T, rs4291-A, Alu II) regarding creatinine clearance variations (P <0.005), but carriers of Alu DD (P <0.02), rs1800764-C (P <0.05), or rs4291-AT (P <0.04) showed better blood pressure lowering effects. The presence of rs2695121-T (P=0.007) or rs5930-A (P=0.039) was associated with systolic blood pressure lowering, whereas rs5930-AA was protective against decrease in creatinine clearance (P=0.019). Statins lowered creatinine clearance for carriers of rs2695121-CT (P=0.026). Interpretation & conclusions: Pharmacological response of blood pressure and creatinine clearance to ACE inhibitors and statins may be genetically mediated.

Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea and creatinine variations in patients with dementia due to Alzheimer disease.

BACKGROUND: Renal function declines according to age and vascular risk factors, whereas few data are available regarding genetically-mediated effects of anti-hypertensives over renal function. OBJECTIVE: To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhibitors (ACEis). METHODS: Consecutive outpatients older than 60 years-old with AD and no history of kidney transplant or dialytic therapy were recruited for prospective correlations regarding variations in fasting blood levels of urea and creatinine in one year, considering ACE genotypes of rs1800764 and rs4291 and their respective haplotypes, and treatment with ACEis along with blood pressure variations. RESULTS: For 190 patients, 152 had arterial hypertension, and 122 used ACEis. Minor allele frequencies were 0.492 for rs1800764-C and 0.337 for rs4291-T, both in Hardy-Weinberg equilibrium. There were no overall significant yearly variations in levels of urea and creatinine, but their concurrent variations were positively correlated (ρ <0.0001). Each A allele of rs4291 led to an yearly urea increase of 3,074 mg/dL, and an yearly creatinine increase of 0.044 mg/dL, while the use of ACEis was protective regarding creatinine variations. The use of ACEis was also protective for carriers of rs1800764-CT/rs4291-AA, while carriers of rs1800764-CT/rs4291-AT had steeper reductions in creatinine levels, particularly when they were treated with ACEis. CONCLUSIONS: Effects of ACEis over creatinine variations are genetically mediated and independent of blood pressure variations in older people with AD.

ANTECEDENTES: El deterioro de la función renal depende de la edad y los factores vasculares. La literatura sobre los efectos de fármacos antihipertensivos mediada genéticamente en la función renal es pobre. OBJETIVO: Estimar las variaciones de urea y creatinina a través del análisis farmacogenético de los efectos antihipertensivos de los inhibidores de la enzima convertidora de angiotensina (iECA) en pacientes con demencia debido a la enfermedad de Alzheimer. MÉTODOS: Fueron reclutados pacientes consecutivos mayores de 60 años de edad con enfermedad de Alzheimer y sin antecedentes de trasplante renal o diálisis. Se determinaron correlaciones prospectivas durante un año entre los cambios en los niveles sanguíneos de urea y creatinina, considerando genotipos y haplotipos de ACE (rs1800764 y rs4291) y el tratamiento con iECA a y las variaciones en la presión arterial. RESULTADOS: De 190 pacientes, 152 presentaron hipertensión, 122 usaron iECA. Las frecuencias de alelos polimórficos fueron de 0.492 para rs1800764-C y 0.337 para rs4291-T, los dos alelos en equilibrio de Hardy-Weinberg. No se determinaron fluctuaciones anuales significativas en los niveles de urea o creatinina, pero sus variaciones concomitantes se asociaron fuertemente (ρ= <0.0001). Cada alelo A de rs4291 condujo a aumentos anuales de 3,074 mg/dL en urea y 0.044 mg/dL en creatinina, mientras que el uso de iECA fue protector para las variaciones en la creatinina. El uso de iECA también fue protector para las personas con rs1800764-CT/rs4291-AA, mientras que los portadores de rs1800764-CT/rs4291-AT tuvieron reducciones de creatinina más altas, particularmente cuando se usó iECA. CONCLUSIÓN: Los efectos de iECA en la variación de la creatinina son genéticamente mediadas e independiente de las variaciones en la presión arterial en pacientes de edad avanzada con la enfermedad de Alzheimer.

Pharmacogenetic effects of angiotensin-converting enzyme inhibitors over age-related urea andcreatinine variations in patients with dementia due to Alzheimer disease / Efectos farmacogenéticos de inhibidores de la enzima convertidora de la angiotensina en variaciones de urea y creatinina asociadas con el envejecimiento en pacientes con demencia de la enfermedad de Alzheimer

Background: Renal function declines according to age and vascular risk factors, whereas few data are available regarding geneticallymediated effects of anti-hypertensives over renal function. Objective: To estimate urea and creatinine variations in dementia due to Alzheimer disease (AD) by way of a pharmacogenetic analysis of the anti-hypertensive effects of angiotensin-converting enzyme inhibitors (ACEis). Methods: Consecutive outpatients older than 60 years-old with AD and no history of kidney transplant or dialytic therapy were recruited for prospective correlations regarding variations in fasting blood levels of urea and creatinine in one year, considering ACE genotypes of rs1800764 and rs4291 and their respective haplotypes, and treatment with ACEis along with blood pressure variations. Results: For 190 patients, 152 had arterial hypertension, and 122 used ACEis. Minor allele frequencies were 0.492 for rs1800764-C and 0.337 for rs4291-T, both in Hardy-Weinberg equilibrium. There were no overall significant yearly variations in levels of urea and creatinine, but their concurrent variations were positively correlated (ρ <0.0001). Each A allele of rs4291 led to an yearly urea increase of 3.074 mg/ dL, and an yearly creatinine increase of 0.044 mg/dL, while the use of ACEis was protective regarding creatinine variations. The use of ACEis was also protective for carriers of rs1800764-CT/rs4291-AA, while carriers of rs1800764-CT/rs4291-AT had steeper reductions in creatinine levels, particularly when they were treated with ACEis. Conclusions: Effects of ACEis over creatinine variations are genetically mediated and independent of blood pressure variations in older people with AD.

Antecedentes: El deterioro de la función renal depende de la edad y los factores vasculares. La literatura sobre los efectos de fármacos antihipertensivos mediada genéticamente en la función renal es pobre. Objetivo: Estimar las variaciones de urea y creatinina a través del análisis farmacogenético de los efectos antihipertensivos de los inhibidores de la enzima convertidora de angiotensina (iECA) en pacientes con demencia debido a la enfermedad de Alzhaimer. Métodos: Fueron reclutados pacientes consecutivos mayores de 60 años de edad con enfermedad de Alzheimer y sin antecedentes de trasplante renal o diálisis. Se determinaron correlaciones prospectivas durante un año entre los cambios en los niveles sanguíneos de urea y creatinina, considerando genotipos y haplotipos de ACE (rs1800764 y rs4291) y el tratamiento con iECA a y las variaciones en la presión arterial. Resultados: De 190 pacientes, 152 presenaron hipertensión, 122 usaron iECA. Las frecuencias de alelos polimórficos fueron de 0.492 para rs1800764-C y 0.337 para rs4291-T, los dos alelos en equilibrio de Hardy-Weinberg. No se determinaron fluctuaciones anuales significativas en los niveles de urea o creatinina, pero sus variaciones concomitantes se asociaron fuertemente (ρ= <0.0001). Cada alelo A de rs4291 condujo a aumentos anuales de 3.074 mg/dL en urea y 0.044 mg/dL en creatinina, mientras que el uso de iECA fue protector para las variaciones en la creatinina. El uso de iECA también fue protector para las personas con rs1800764-CT/rs4291-AA, mientras que los portadores de rs1800764-CT/rs4291-AT tuvieron reducciones de creatinina más altas, particularmente cuando se usó iECA. Conclusión: Los efectos de iECA en la variación de la creatinina son genéticamente mediadas e independiente de las variaciones en la presión arterial en pacientes de edad avanzada con la enfermedad de Alzheimer.